Status:
COMPLETED
Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%
Lead Sponsor:
Allergan
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolam...
Eligibility Criteria
Inclusion
- Glaucoma or ocular hypertension in both eyes
- Currently being treated with latanoprost 0.005% QD
- IOP greater than or equal to 18mm Hg on latanoprost 0.005%
- Best-corrected VA of 20/200 or better in each eye
- Visual field within 6 months of study entry
Exclusion
- Secondary glaucoma
- Active intraocular inflammation or macular edema
- Intraocular surgery or laser surgery within the past 3 months
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00440141
Start Date
July 1 2006
End Date
March 1 2007
Last Update
January 2 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Atlanta, Georgia, United States